Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16558944 | 0.88 | HSD17B10 (0.36) | NR1H2NR1H3CYP1A2POLBCYP3A4 | |
| SCHEMBL19972949 | 0.88 | NFKB1 (0.37) | NFKB1NFKB2RELADDB1CRBN | |
| SCHEMBL19972951 | 0.88 | NFKB1 (0.37) | NFKB1NFKB2RELADDB1CRBN | |
| SCHEMBL19972948 | 0.88 | NFKB1 (0.37) | NFKB1NFKB2RELADDB1CRBN | |
| SCHEMBL16558955 | 0.84 | NR1H3 (0.34) | DDB1CRBNNR1H2NR1H3MAP4K4 | |
| SCHEMBL19978912 | 0.80 | NFKB1 (0.34) | NFKB1NFKB2RELA | |
| SCHEMBL16558943 | 0.80 | NFKB1 (0.36) | NFKB1NFKB2RELANR1H2NR1H3 | |
| SCHEMBL16558942 | 0.80 | MEN1 (0.40) | NFKB1NFKB2RELANR1H2NR1H3 | |
| SCHEMBL16558954 | 0.75 | USP30 (0.35) | NR1H2NR1H3JAK2JAK1USP30 | |
| SCHEMBL31286151 | 0.74 | GPR119 (0.37) | NR1H2NR1H3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | NFKB1 1842/4885NFKB2 2601/4885RELA 1379/4885 |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | LCT, MGAM, SI | NFKB1 1842/4885NFKB2 2601/4885RELA 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.